Stocktoria
Q32 Bio Inc. QTTB
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-03-28
Chart by TradingView
3/9
Piotroski F — financial health
-2.11
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $53.7M | $0 | -$6.7M | $3.2M | $34.0M |
| Operating income | $16.9M | -$66.1M | -$48.3M | -$133.3M | -$95.9M |
| Net income | $29.8M | -$47.7M | -$53.7M | -$5.0M | -$95.8M |
| Operating cash flow | -$33.5M | -$67.7M | -$18.7M | -$113.7M | -$109.8M |
| Free cash flow | -$33.5M | -$67.8M | -$18.7M | -$114.9M | -$112.1M |
| Total assets | $61.8M | $92.3M | $47.1M | $228.5M | $211.7M |
| Total liabilities | $19.8M | $86.7M | $118.5M | $50.5M | $42.1M |
| Shareholders' equity | $42.0M | $5.7M | -$182.9M | -$130.7M | $169.7M |
| Ratios | |||||
| Operating margin | 31.5% | — | 725.5% | -4154.6% | -282.4% |
| Net margin | 55.5% | — | 808.0% | -156.0% | -281.9% |
| FCF margin | -62.4% | — | 280.9% | -3583.1% | -330.1% |
| Return on assets | 48.3% | -51.7% | -114.2% | -2.2% | -45.2% |
| Return on equity | 71.0% | -841.1% | 29.4% | 3.8% | -56.4% |
| Current ratio | 4.85 | 4.97 | 2.04 | 8.02 | 11.14 |
| Revenue growth | — | -100.0% | -307.3% | -90.6% | 1157.3% |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 206,915 | $1.3M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -2.11 (distress)
- Working capital / assets 0.707
- Retained earnings / assets -3.318
- EBIT / assets 0.274
- Equity / liabilities 2.126
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001661998 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.